Accendra Health sells first of two non-core assets, expects about $45 million cash injection
ACH•Accendra outlines two asset sales
Accendra Health outlined sales of two non-core assets, targeting about $45 million of cash proceeds in the third and fourth quarters.
EBITDA impact expected to be minimal
Adjusted EBITDA impact is expected to be de minimis.
First divestiture closed in the third quarter
One divestiture closed in the third quarter; the second is expected to close before year-end.
